Total Funding
26
8
Total FundingSeries B raised
Growth Score
-1 pts
Heat Score
-15 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
51293
Goldfinch is a clinical-stage biotech company focused on discovering and developing precision therapies for patients with kidney disease.
Anthony G. Johnson: President and CEOPast Role: AstraZeneca, SVP, Early Clinical Development
Peter Mundel: Co-Founder & Executive Scientific AdvisorPast Role: Massachusetts General Hospital, Associate Professor of Medicine
About the Company
Goldfinch is a clinical-stage biotech company focused on discovering and developing precision therapies for patients with kidney disease. It is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. Its Product Engine will
industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets to treat progressive kidney disease.
The company was founded in 2016 and is based in Cambridge, Massachusetts.
